Royal Bank of Canada began coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report released on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $77.00 price target on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on RARE. JPMorgan Chase & Co. upped their […]